Shares of vTv Therapeutics Inc. (VTVT) are surging over 67% on Wednesday morning after the clinical stage biopharmaceutical company announced $51 million in private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
By Josh Beckerman Shares of vTv Therapeutics more than doubled after the company raised $51 million in a private placement, which will be used to fund the.
VTv Therapeutics stock surge, fueled by a $51M private placement. Learn about their clinical-stage biopharmaceutical focus on cadisegliatin for type 1 diabetes. Stock up 111.8% at $18.
Wednesday, vTv Therapeutics Inc VTVT shares are soaring on a robust session volume of 2.7 million, compared to the average volume of 31.92 K as per the data…
HC Wainwright reissued their buy rating on shares of aTyr Pharma (NASDAQ:LIFE – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $35.00 price target on the biotechnology company’s stock. Separately, StockNews.com lowered aTyr Pharma from a hold rating to a sell rating in a research […]